Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139580 · ClinicalTrials.gov registry record · Phase 3
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
A Phase 3 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 363
- Enrollment target
NCT01139580: Completed Phase 3 study, sponsored by Stiefel, a GSK Company.
NCT01139580 is a Phase 3 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 363 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01139580, a Phase 3 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 363 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
Primary Outcome
The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe
Interventions
- DRUG Vehicle Foam
- DRUG Calcipotriene Foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
What the finished NCT01139580 record still lists
NCT01139580 is an interventional study that assigns participants to a tested intervention. The registered 363 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT01139580 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01139580 about?
NCT01139580 is a clinical study titled "The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis". The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
What is the current status of trial NCT01139580?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2010-05. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01139580?
The interventions under investigation include: Vehicle Foam (DRUG), Calcipotriene Foam (DRUG).
Who is sponsoring clinical trial NCT01139580?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01139580's enrollment target sits among peer trials
363 1005th of 2000 higher than 994 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia